Puataweepong Putipun, Dhanachai Mantana, Hansasuta Ake, Saetia Kriangsak, Dangprasert Somjai, Sitathanee Chomporn, Yongvithisatid Pornpan
Radiation and Oncology Unit, Department of Radiology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand Email :
Asian Pac J Cancer Prev. 2016;17(7):3271-6.
Intracranial nonvestibular schwannomas arising from various cranial nerves excluding CN VIII are uncommon. Recently, stereotactic radiosurgery (SRS) and fractionated stereotactic radiotherapy (SRT) have been widely reported as effective treatment modalities for nonvestibular schwannomas. The purpose of this study was to study the long term clinical outcome for nonvestibular schwannomas treated with both XKnife and CyberKnife (CK) radiosurgery at one institution.
From 2004 to 2013, fiftytwo nonvestibular schwannoma patients were included in this study, 33 patients (63%) were treated with CK, and 19 (37%) were treated with XKnife. The majority of the tumors were jugular foramen schwannomas (38%) and trigeminal schwannomas (27%). HSRT was given for 45 patients (86%), whereas CSRT was for 6 (12%) and SRS for 1 (2%).
The median pretreatment volume was 9.4 cm3 (range, 0.5752 cm3). With the median follow up time of 36 months (range, 3135), the 3 and 5 year progression free survival was 94 % and 88%, respectively. Tumor size was decreased in 13 (25%), stable in 29 (56%), and increased in 10 (19%). Among the latter, 3 (30%) required additional treatment because of neurologic deterioration. No patient was found to develop any new cranial nerve deficit after SRS/SRT.
These data confirmed that SRS/ SRT provide high tumor control rates with low complications. Large volume tumors and cystic expansion after radiation should be carefully followed up with neurological examination and MRI, because it may frequently cause neurological deterioration requiring further surgery.
起源于除第八对脑神经外的各种颅神经的颅内非前庭神经鞘瘤并不常见。最近,立体定向放射外科(SRS)和分次立体定向放射治疗(SRT)作为非前庭神经鞘瘤的有效治疗方式已被广泛报道。本研究的目的是研究在一家机构使用X刀和射波刀(CK)放射外科治疗非前庭神经鞘瘤的长期临床结果。
2004年至2013年,本研究纳入了52例非前庭神经鞘瘤患者,3例(63%)接受了CK治疗,19例(37%)接受了X刀治疗。大多数肿瘤为颈静脉孔神经鞘瘤(38%)和三叉神经鞘瘤(27%)。45例(86%)患者接受了高分割立体定向放射治疗(HSRT),6例(12%)接受了常规分割立体定向放射治疗(CSRT),1例(2%)接受了SRS。
治疗前肿瘤体积中位数为9.4 cm³(范围,0.5752 cm³)。中位随访时间为36个月(范围,3至135个月),3年和5年无进展生存率分别为94%和88%。13例(25%)肿瘤体积缩小,29例(56%)稳定,10例(19%)增大。在后者中,3例(30%)因神经功能恶化需要额外治疗。SRS/SRT后未发现患者出现任何新的颅神经缺损。
这些数据证实SRS/SRT具有高肿瘤控制率和低并发症。对于体积较大的肿瘤以及放疗后出现囊性扩张的情况,应通过神经学检查和MRI进行仔细随访,因为这可能经常导致神经功能恶化而需要进一步手术。